Searched for
INTERCHANGEABLE INSULINS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...- Almond Milk vs Oat Milk: Which Raises Blood Sugar More?Plant-based milks, often seen as interchangeable, have vastly different metabolic impacts. Oat milk, due to processing, converts to simple ...
- ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar ShawBiocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Biocon Biologics expands collaboration with Civica to supply affordable insulin in USBiocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...
- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
- Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
- USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...
- Biocon's growth drivers are in place: 5 reasons it is this week's stock pickImproving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...
- Biocon eyes $30b US insulin market via its biosimilarsWith the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
- Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...
- Biocon's biosimilars progressAnalysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...
- Biosimilar products development gets a USFDA norms boostA biosimilar is a product that is similar to a biologic, which in turn is any drug produced through a biological route rather than chemical...
Load More
